DICE Therapeutics (DICE) Financials

$47.55

$0.00 (0.00%)

As on 18-Aug-2023 09:30EDT

Market cap

$2,271 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

5.9

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Operating Revenue	--	--	1.13	0.86	5.78	--
Cost of Revenue	--	--	--	--	--	--
Gross Profit	--	--	1.13	0.86	5.78	--
Operating Expenses	118.69	88.22	48.73	24.58	19.32	--
Operating Profit (EBIT)	-118.69	-88.22	-47.60	-23.72	-13.55	--
Other Income	14.82	4.47	-1.24	--	--	--
Profit before Tax	-104.24	-83.89	-48.96	-23.74	-12.94	--
Provision for Tax	-2.48	-2.22	-0.49	0.01	0.03	--
Profit after Tax (Net Income)	-97.08	-81.66	-48.47	-23.75	-12.96	--
Minority Interest	--	--	--	--	--	--
Consolidated Profit	-104.24	-83.89	-48.96	-23.74	-12.94	--

Liabilities ($ Mln)	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Shareholder's Funds	519.06	-187.59	-103.71	-53.15	-29.62	--
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	11.05	11.84	1.92	107.72	57.10	--
Current Liabilities	20.57	15.15	10.88	9.29	3.71	--
Total Liabilities	571.24	593.98	325.75	63.86	31.18	--

Assets ($ Mln)	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Non-Current Assets	18.37	16.22	1.84	1.81	2.09	--
Current Assets	532.30	577.76	323.91	62.05	29.09	--
Total Assets	571.24	-160.60	-90.90	63.86	31.18	--
Total Debt*	12.58	13.27	2.40	0.10	0.22	--
Net Current Assets	511.73	562.61	313.03	52.76	25.39	--

Cashflow ($ Mln)	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Cash From Operating Activities	--	-64.32	-39.29	-20.68	-16.30	--
Cash Flow from Investing Activities	--	87.49	-204.62	18.00	-19.13	--
Cash from Financing Activities	--	322.25	300.25	53.90	-0.28	--
Net Cash Inflow / Outflow	--	345.42	56.34	--	--	--

Financials Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Adjusted EPS ($)	-2.18	-1.80	-1.30	-1.02	--	--
Cash EPS ($)	--	-1.74	-1.29	-0.99	--	--
Adjusted Book Value ($)	--	--	--	--	--	--
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	-1.42	-1.06	-0.89	--	--
Free Cash Flow per Share ($)	--	-1.47	-1.08	-0.90	--	--

Profitability Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
ROCE (%)	--	59.25	62.80	57.62	--	--
ROE (%)	--	56.07	61.81	57.39	--	--
ROA (%)	-21.92	-17.76	-24.88	-49.98	--	--
EBIT Margin (%)	--	--	-4,231.38	-2,748.67	-234.58	--
Net Margin (%)	-654.97	-1,825.30	42,149.57	-2,752.26	-224.48	--
Cash Profit Margin (%)	--	--	--	--	--	--

Growth Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Revenue Growth (%)	--	-1.00	0.30	-0.85	--	--
EBIT Growth (%)	-56.17	-85.33	-100.68	-75.10	--	--
Net Profit Growth (%)	-31.94	-68.48	-104.08	-83.22	--	--
EPS Growth (%)	42.62	-0.38	-0.28	--	--	--
Book Value Growth (%)	47.49	--	--	--	--	--

Valuation Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Price / Earnings	--	-17.36	-19.40	--	--	--
Price / Book Value	5.91	-7.56	-9.07	--	--	--
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	-17.30	-10.32	-13.14	--	--	--
Close Price ($)	46.46	31.20	25.31	--	--	--
High Price ($)	46.90	45.99	40.50	--	--	--
Low Price ($)	14.42	12.64	20.94	--	--	--
Market Cap ($ Cr)	2,270.79	--	--	--	--	--

Solvency Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Debt to Equity	--	-0.07	-0.02	0.00	-0.01	--
Short term debt to equity ratio	0.00	-0.01	0.00	0.00	0.00	--
Current Ratio	25.88	38.14	29.77	6.68	7.85	--
Quick Ratio	25.88	--	29.95	--	--	--
Interest Coverage	-15.08	-129.93	-273.58	-1,824.69	-521.04	--

Operating Efficiency Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Debtors to sales (%)	--	--	177.78	231.75	34.63	--
Asset Turnover	--	--	0.01	0.02	--	--
Receivable days	--	--	649.33	846.47	126.49	--
Inventory Days	--	--	--	--	--	--
Payable days	--	--	--	--	--	--
Cash Conversion Cycle	--	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.